CAI vs VCYT
CAI: Caris Life Sciences delivers precision oncology and molecular profiling solutions that help biopharma companies and physicians make treatment decisions through comprehensive tumor analysis. VCYT: Veracyte is a genomics-focused diagnostics company providing high-value clinical tests to improve cancer detection and treatment guidance for patients worldwide.
Side-by-side fundamentals
| Metric | CAI | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $16.09 | $59.78 | |
| Market cap as of 2026-07-31 | $4.4B | $4.8B | |
| P/E as of 2026-07-31 | 141.51 | 55.37 | VCYT lower |
| PEG as of 2026-07-31 | -0.97 | 0.32 | CAI lower |
| Net margin as of 2026-07-31 | +3.8% | +16.3% | VCYT higher |
| Gross margin as of 2026-07-31 | +68.7% | +70.9% | VCYT higher |
| Operating margin as of 2026-07-31 | +9.8% | +15.1% | VCYT higher |
| ROE as of 2026-07-31 | +6.5% | +6.9% | VCYT higher |
| ROA as of 2026-07-31 | +3.2% | +6.3% | VCYT higher |
| Debt / equity as of 2026-07-31 | 0.64 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-07-31 | +78.8% | +16.9% | CAI higher |
| Revenue CAGR (3y) SEC XBRL | +62.9% | +20.4% | CAI higher |
| Beta as of 2026-07-31 | 1.33 | 1.39 | |
| 1-year return as of 2026-07-30 close | -45.5% | +149.4% | VCYT higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.